Localized prostate cancer refers to prostate cancer confined to the primary site without distant spread. It generally has an excellent prognosis, with very high 5-year relative survival when diagnosed at this stage.
Candel initiated the Phase 3 AURORA trial of aglatimagene in NSCLC and plans a Q4 2026 BLA in localized prostate cancer, with a potential 2027 launch. The company also appointed a Chief Commercial Officer.
A large clinical trial found that adding apalutamide to hormone therapy before and after prostate cancer surgery improves outcomes for high-risk patients. NHS England will roll out SABR radiotherapy requiring only five sessions, and new ctDNA and robotic biopsy technologies are advancing prostate cancer care.
Candel Therapeutics secured $100M royalty funding for CAN-2409 and plans a Q4 2026 BLA submission in prostate cancer. Updated NSCLC phase 2a data showed median overall survival of 25.4 months, with a phase 3 trial planned for Q2 2026.
A multi-institutional study found that pairing an investigational immunotherapy with hormone therapy before surgery reduced regulatory T cells in prostate tumors and improved cancer-free outcomes in high-risk patients.
Candel Therapeutics announced a $100 million royalty funding agreement with RTW Investments, contingent on FDA approval of aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer, with tiered royalties on U.S. net sales.
A matched analysis of 923 men found salvage focal therapy and radical prostatectomy achieved comparable 10-year cancer-specific survival for prostate cancer recurring after radiotherapy, though surgery carried significantly higher complication rates.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07757490 |
Sonablate HIFU International Registry for PC & BPH Patients |
RECRUITING | |
| NCT07747493 |
68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy |
NOT_YET_RECRUITING | NA |
| NCT07650448 |
WATER IV PCa (AS Sub-study) |
NOT_YET_RECRUITING | NA |
| NCT07426055 |
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer |
RECRUITING | PHASE2/PHASE3 |
| NCT06966778 |
Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial |
RECRUITING | NA |
| NCT06825091 |
Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE) |
RECRUITING | PHASE3 |
| NCT06651632 |
WATER IV Prostate Cancer |
ACTIVE_NOT_RECRUITING | NA |
| NCT06362577 |
Clinical Study of HIFU for Localized Prostate Cancer |
RECRUITING | |
| NCT06325995 |
Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer |
RECRUITING | NA |
| NCT06325774 |
Radical Hypofractionated Radiotherapy for Localized Prostate Cancer |
RECRUITING | NA |
